The company is continuing with the evaluation of canakinumab in lung cancer, and is applying findings to the overall lung cancer development plan
The company’s wide therapeutic portfolio helped to sustain growth despite changing market demand
This strategic collaboration will enable continued innovation in cancer care
Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years in a randomized Phase 3 trial, supporting potential as a best-in-class option
The platform has seen an overall growth of 84% in the number of people seeking consultations for skin-related issues
Incidences of Non-alcoholic Fatty Liver Disease (NAFLD) have been rising exponentially worldwide and are associated with co-morbidities including obesity, diabetes, hypertension and metabolic disorders
The company reported 4% topline growth during the quarter driven by steady revenues in the Pharmaceuticals segment and robust growth in the Contract Research and Development Services (CRDS) segment
The test combines sensitivity with speed and is designed to be used in health care settings to aid with rapid diagnosis of Covid-19
India reports 18 lakh stroke cases a year with 25 per cent patients below the age of 50
Following the pre-NDA meeting with the U.S. FDA, the companies confirmed the current efficacy and safety databases are expected to be adequate for filing with confirmed pathways for MDD and PPD
Subscribe To Our Newsletter & Stay Updated
